Loading
AZD9750 is an experimental protein degrader from AstraZeneca in phase 2 trials for prostate cancer, aimed at Androgen receptor.
AZD9750 is a protein degrader developed by AstraZeneca. Its target is Androgen receptor (the sponsor names androgen receptor (AR)). The sponsor states: An AR-PROTAC that binds the androgen receptor and recruits it for proteasomal degradation, rather than simply inhibiting its function. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in prostate cancer. The largest, NCT07336446, plans to enrol 300 participants with primary completion expected 2029-01-26. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
An AR-PROTAC that binds the androgen receptor and recruits it for proteasomal degradation, rather than simply inhibiting its function. Connects to Androgen receptor.
1.AZD9750 binds Androgen receptor with one end and an E3 ubiquitin ligase with the other.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD9750" OR ABSTRACT:"AZD9750") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD9750, not a curated reading list.
Shares AstraZeneca, Prostate cancer and the tag pipeline.
Shares AstraZeneca, Prostate cancer and the tag pipeline.
Shares Androgen receptor, Prostate cancer and the tag pipeline.
Shares Androgen receptor, Prostate cancer and the tag pipeline.
Shares AstraZeneca, Prostate cancer and the tag pipeline.
Shares A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs, AstraZeneca, Prostate cancer and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.